Peng, W., Shi, M., Hu, B., Jia, J., Li, X., Wang, N., . . . Ma, L. (2025). Nanotechnology-leveraged CRISPR/Cas systems. Molecular Cancer, 24(1), 1. https://doi.org/10.1186/s12943-024-02222-5
Chicago-referens (17:e uppl.)Peng, Weipan, Mengting Shi, Bin Hu, Jingyu Jia, Xinyue Li, Nan Wang, Shuli Man, Shengying Ye, och Long Ma. "Nanotechnology-leveraged CRISPR/Cas Systems." Molecular Cancer 24, no. 1 (2025): 1. https://doi.org/10.1186/s12943-024-02222-5.
MLA-referens (9:e uppl.)Peng, Weipan, et al. "Nanotechnology-leveraged CRISPR/Cas Systems." Molecular Cancer, vol. 24, no. 1, 2025, p. 1, https://doi.org/10.1186/s12943-024-02222-5.
Varning: dessa hänvisningar är inte alltid fullständigt riktiga.